<DOC>
	<DOCNO>NCT02382263</DOCNO>
	<brief_summary>In list cancer mortality type cancer pancreatic cancer rank 4th USA 6th Europe . The estimate figure 2010 USA 42,000 new case 36,000 death pancreatic cancer . The survival rate 5 year diagnosis 4.6 % USA . In Europe figure similar , survival 1 , 3 5 year 16 % , 6 % 4 % , respectively . Most patient diagnose advanced stage longer operable , treatment goal often prolongation survival palliation symptom . The aim study explore whether new combination nab-paclitaxel plus gemcitabine therapeutic advance fragile population assume modification dose schedule administration may necessary patient good performance status . It ultimately find clinical benefit combination , first make sure dose schedule combination tolerable fragile patient . For , investigator choose design include two stage : first step aim choose safe treatment regimen patient among group treatment regimen use clinical trial . The second step evaluate effectiveness two regimen well result previous step .</brief_summary>
	<brief_title>Nab-paclitaxel Combination With Gemcitabine Fragile Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients 18 year old ; Patients histological , possible , cytologic confirm adenocarcinoma pancreas . Patients metastatic pancreatic cancer ; Patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) = 2 Adequate hematopoietic , hepatic renal function : Neutrophil count &gt; = 1.5 x 10*9/L ; Platelet count &gt; = 100 x 10*9/L ; Bilirubin &lt; = 1.5 x ULN ; AST and/or ALT &lt; = 2.5 x ULN ; Serum creatinine &lt; = 1.5 x ULN . Investigators must ensure patient enrol study available study procedure , include tumor biopsy , chemotherapy treatment , follow . Investigators must ensure patient ability understand requirement study provide sign informed consent . Women childbearing potential men wish participate study must agree use adequate contraception since signing inform consent least 3 month stop study medication ; Signed Informed Consent . Active uncontrolled infection serious illness medical condition could interfere patient eligibility treatment ; History psychiatric condition might impair patient ? ability understand comply requirement study provide informed consent ; Concurrent anticancer therapy ; Pregnant breastfeed woman ( document method birth control require reproductive potential ) ; History allergic reaction attribute compound similar chemical biologic composition study drug ; History life threaten reaction gemcitabine abraxane ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) &lt; =1 . Previous treatment chemotherapy chemoradiotherapy advance pancreatic cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced pancreatic cancer</keyword>
	<keyword>Fragile</keyword>
	<keyword>Nab-paclitaxel</keyword>
</DOC>